Biogen (BIIB) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenue reached $2.43 billion, up 6.1% year-over-year, driven by rare disease, new product launches, and contract manufacturing growth.

• Net income attributable to Biogen was $240.5 million, with GAAP diluted EPS of $1.64 and Non-GAAP diluted EPS of $3.02, both impacted by a $165 million upfront payment to Stoke Therapeutics.

• MS product revenue declined 11%–11.4% due to increased competition and generic entrants, while rare disease revenue rose 32.9%–33% on new launches and one-time items.

• Significant pipeline progress included the HI-Bio acquisition, FDA Fast Track for BIIB080, and new collaborations with Stoke Therapeutics and Royalty Pharma.

• LEQEMBI and SKYCLARYS received new international approvals, supporting global expansion.

Financial highlights

• Product revenue was $1.73 billion, up 0.9% year-over-year; rare disease revenue increased $139.4 million, offsetting a $122.9 million MS revenue decline.

• Revenue from launch products grew 22% sequentially and 105% year-over-year to $200 million.

• Free cash flow for Q1 2025 was $222 million; cash and cash equivalents totaled $2.6 billion, with net debt of $3.7 billion as of March 31, 2025.

• GAAP diluted EPS declined 39% year-over-year to $1.64; Non-GAAP diluted EPS declined 18% to $3.02, both reflecting the $0.95 per share impact from the Stoke payment.

• Cost of sales rose 16.1% to $629.3 million, mainly due to contract manufacturing and SKYCLARYS amortization.

Outlook and guidance

• Full-year 2025 Non-GAAP diluted EPS guidance is $14.50–$15.50, reflecting the Stoke payment and a $0.20 FX benefit.

• Total revenue for 2025 is expected to decline by a mid-single-digit percentage, mainly due to MS revenue decline, partially offset by launch product growth.

• Fit for Growth program is on track to deliver $1 billion gross and $800 million net savings by end of 2025; combined Non-GAAP R&D and SG&A expense expected to total ~$3.9 billion in 2025.

• No material impact expected from announced U.S. or Chinese tariffs in 2025; guidance assumes current FX rates and tariff landscape.

• IRA Medicare Part D redesign is anticipated to have a modest net unfavorable impact of $50–100 million on 2025 revenue.